{"id":"mtor-inhibitor-everolimus","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Stomatitis/mouth ulcers"},{"rate":"30-40","effect":"Rash"},{"rate":"25-35","effect":"Diarrhea"},{"rate":"25-30","effect":"Fatigue"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Anemia"},{"rate":"15-20","effect":"Hyperglycemia"},{"rate":"15-20","effect":"Hyperlipidemia"},{"rate":"10-20","effect":"Infections"}]},"_chembl":{"chemblId":"CHEMBL1908360","moleculeType":"Small molecule","molecularWeight":"958.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"mTOR is a central regulator of cell metabolism, growth, and survival. By blocking mTOR signaling, everolimus suppresses cell proliferation and angiogenesis, making it effective in cancers and certain proliferative diseases. It also has immunomodulatory effects that enhance T-cell activation in some contexts.","oneSentence":"Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:02.006Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced renal cell carcinoma"},{"name":"Breast cancer (hormone receptor-positive, HER2-negative)"},{"name":"Neuroendocrine tumors of pancreatic origin"},{"name":"Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex"},{"name":"Renal angiomyolipoma associated with tuberous sclerosis complex"}]},"trialDetails":[{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":"Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm","enrollment":70},{"nctId":"NCT05773274","phase":"PHASE2","title":"Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-12","conditions":"Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1","enrollment":100},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT05573126","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","status":"RECRUITING","sponsor":"Ellipses Pharma","startDate":"2023-01-11","conditions":"Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer","enrollment":95},{"nctId":"NCT03950609","phase":"PHASE2","title":"Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-07-30","conditions":"Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1","enrollment":36},{"nctId":"NCT04485559","phase":"PHASE1","title":"Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2020-12-09","conditions":"Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High Grade Glioma","enrollment":50},{"nctId":"NCT05012371","phase":"PHASE2","title":"Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-16","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8","enrollment":90},{"nctId":"NCT07144150","phase":"NA","title":"EVERO Drug-coated Balloon (DCB) Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Cook Research Incorporated","startDate":"2026-02","conditions":"Peripheral Vascular Disease, Peripheral Arterial Disease","enrollment":410},{"nctId":"NCT04895748","phase":"PHASE1","title":"DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-30","conditions":"Carcinoma, Renal Cell","enrollment":40},{"nctId":"NCT02184416","phase":"","title":"Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-10-31","conditions":"Metastatic Renal Cell Carcinoma (mRCC)","enrollment":554},{"nctId":"NCT07426484","phase":"PHASE4","title":"Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-07","conditions":"Cutaneous Squamous Cell Carcinoma, Skin Cancer","enrollment":80},{"nctId":"NCT04199026","phase":"NA","title":"Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-25","conditions":"Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma","enrollment":20},{"nctId":"NCT02397083","phase":"PHASE2","title":"Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-23","conditions":"Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma","enrollment":102},{"nctId":"NCT03008408","phase":"PHASE2","title":"A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-18","conditions":"Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Carcinoma","enrollment":90},{"nctId":"NCT05949658","phase":"PHASE1","title":"Rapalog Pharmacology (RAP PAC) Study","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2024-05-15","conditions":"Aging","enrollment":72},{"nctId":"NCT06727305","phase":"PHASE1, PHASE2","title":"MTOR Inhibitors in Older Adults","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02","conditions":"Aging","enrollment":60},{"nctId":"NCT05933395","phase":"PHASE2","title":"Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2024-09-23","conditions":"Advanced Breast Cancer","enrollment":135},{"nctId":"NCT01087554","phase":"PHASE1","title":"Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-03","conditions":"Advanced Cancer","enrollment":249},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT03065387","phase":"PHASE1","title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-31","conditions":"Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation","enrollment":93},{"nctId":"NCT07002177","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","status":"RECRUITING","sponsor":"Forward Pharmaceuticals Co., Ltd.","startDate":"2025-06-01","conditions":"Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II","enrollment":196},{"nctId":"NCT04542733","phase":"NA","title":"The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation Recipient","status":"RECRUITING","sponsor":"King Chulalongkorn Memorial Hospital","startDate":"2021-02-10","conditions":"Kidney Transplant Infection, BK Virus Infection","enrollment":50},{"nctId":"NCT07062965","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-05","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT05835999","phase":"PHASE2","title":"Everolimus Aging Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-03-24","conditions":"Aging, Insulin Resistance","enrollment":106},{"nctId":"NCT03740334","phase":"PHASE1","title":"Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-01-30","conditions":"Acute Lymphoblastic Leukemia ALL","enrollment":45},{"nctId":"NCT02321501","phase":"PHASE1","title":"Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06-22","conditions":"ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":37},{"nctId":"NCT01582191","phase":"PHASE1","title":"Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-05-14","conditions":"Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm","enrollment":151},{"nctId":"NCT05508906","phase":"PHASE1","title":"Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2022-08-31","conditions":"Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":190},{"nctId":"NCT07191353","phase":"PHASE2","title":"Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women","status":"NOT_YET_RECRUITING","sponsor":"Odense University Hospital","startDate":"2025-09-30","conditions":"Healthy, Osteopenia, Osteoporosis Risk","enrollment":148},{"nctId":"NCT07173556","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-09","conditions":"Advanced Breast Cancer","enrollment":96},{"nctId":"NCT07037238","phase":"PHASE2","title":"An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2025-07-01","conditions":"Vascular Malformations","enrollment":10},{"nctId":"NCT06658093","phase":"EARLY_PHASE1","title":"RESTOR: PK/PD mTORi Inhibition in Older Adults","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2025-08-13","conditions":"Aging","enrollment":194},{"nctId":"NCT03112603","phase":"PHASE3","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-29","conditions":"Graft-versus-host Disease (GVHD)","enrollment":330},{"nctId":"NCT05132166","phase":"PHASE2","title":"A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-12-22","conditions":"Graft Vs Host Disease","enrollment":50},{"nctId":"NCT03697408","phase":"PHASE1, PHASE2","title":"Itacitinib + Everolimus in Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2019-02-11","conditions":"Classical Hodgkin Lymphoma","enrollment":23},{"nctId":"NCT06994572","phase":"PHASE1","title":"Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Captor Therapeutics S.A.","startDate":"2025-05-26","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":141},{"nctId":"NCT03493152","phase":"","title":"Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)","status":"NO_LONGER_AVAILABLE","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"","conditions":"Gastrointestinal Stromal Tumor","enrollment":""},{"nctId":"NCT03493165","phase":"","title":"Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)","status":"NO_LONGER_AVAILABLE","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"","conditions":"Uterine Sarcoma","enrollment":""},{"nctId":"NCT01313559","phase":"PHASE2","title":"Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-06","conditions":"Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer, Prostate Cancer","enrollment":6},{"nctId":"NCT03324373","phase":"PHASE1","title":"Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)","status":"COMPLETED","sponsor":"Yousef Zakharia","startDate":"2019-03-20","conditions":"Renal Cell Carcinoma","enrollment":11},{"nctId":"NCT04339062","phase":"PHASE1, PHASE2","title":"Cemiplimab in AlloSCT/SOT Recipients With CSCC","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-11-03","conditions":"Cutaneous Squamous Cell Carcinoma, Advanced Cancer","enrollment":12},{"nctId":"NCT04965688","phase":"PHASE2","title":"Biology Guided Therapy for Breast Cancer for ER Positive","status":"TERMINATED","sponsor":"Inova Health Care Services","startDate":"2021-08-08","conditions":"Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":2},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT03114527","phase":"PHASE2","title":"Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2017-08-08","conditions":"Soft Tissue Sarcoma","enrollment":48},{"nctId":"NCT06504225","phase":"","title":"EVEROLD LONG TERM FOLLOW-UP","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2024-08-23","conditions":"Transplant; Complication, Failure","enrollment":260},{"nctId":"NCT02432560","phase":"","title":"Safety and Durability of Sirolimus for Treatment of LAM","status":"RECRUITING","sponsor":"University of Cincinnati","startDate":"2015-03","conditions":"Lymphangioleiomyomatosis","enrollment":600},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT02216786","phase":"PHASE2","title":"A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-01-16","conditions":"Estrogen Receptor Positive Breast Cancer","enrollment":333},{"nctId":"NCT05293964","phase":"PHASE1","title":"Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2022-05-18","conditions":"Breast Cancer","enrollment":214},{"nctId":"NCT05594095","phase":"PHASE2","title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-12-30","conditions":"Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor","enrollment":620},{"nctId":"NCT00811590","phase":"PHASE2","title":"Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome","status":"TERMINATED","sponsor":"University of Utah","startDate":"2008-11","conditions":"Peutz-Jeghers Syndrome","enrollment":3},{"nctId":"NCT06584773","phase":"PHASE4","title":"Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-06","conditions":"Disorder Related to Renal Transplantation","enrollment":80},{"nctId":"NCT04185831","phase":"PHASE2","title":"A MolEcularly Guided Anti-Cancer Drug Off-Label Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Uppsala University Hospital","startDate":"2020-10-20","conditions":"Solid Tumor","enrollment":167},{"nctId":"NCT00655655","phase":"PHASE1","title":"Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2004-12","conditions":"Gastrinoma, Glucagonoma, Insulinoma","enrollment":96},{"nctId":"NCT05833815","phase":"PHASE2, PHASE3","title":"Addition of Everolimus to Standard of Care in Carcinoma Gallbladder","status":"RECRUITING","sponsor":"Banaras Hindu University","startDate":"2022-11-01","conditions":"Gallbladder Cancer","enrollment":56},{"nctId":"NCT04562532","phase":"NA","title":"Firehawk Rapamycin Target Eluting Coronary Stent North American Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai MicroPort Medical (Group) Co., Ltd.","startDate":"2021-02-17","conditions":"Coronary Artery Disease","enrollment":1720},{"nctId":"NCT01523977","phase":"PHASE1","title":"Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2011-11","conditions":"Acute Lymphoblastic Leukemia","enrollment":22},{"nctId":"NCT04803318","phase":"PHASE2","title":"Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2021-01-01","conditions":"Solid Tumor, Adult, Hepatocellular Carcinoma","enrollment":100},{"nctId":"NCT03955172","phase":"NA","title":"Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2020-12-03","conditions":"Kidney Transplant Failure and Rejection","enrollment":20},{"nctId":"NCT06301386","phase":"PHASE2","title":"Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-04-01","conditions":"Colon Cancer","enrollment":25},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT04936971","phase":"PHASE4","title":"Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response","status":"WITHDRAWN","sponsor":"Edoardo Melilli","startDate":"2021-09","conditions":"Kidney Transplantation, Cytomegalovirus Infections","enrollment":""},{"nctId":"NCT02456857","phase":"PHASE2","title":"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-01-12","conditions":"Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma","enrollment":17},{"nctId":"NCT05949541","phase":"PHASE2","title":"Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-07-26","conditions":"Breast Cancer, Advanced Breast Cancer","enrollment":265},{"nctId":"NCT05954442","phase":"PHASE3","title":"Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-09-13","conditions":"Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation","enrollment":203},{"nctId":"NCT02332902","phase":"PHASE2","title":"Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2015-02","conditions":"Neurofibromatosis 1","enrollment":24},{"nctId":"NCT02520180","phase":"NA","title":"Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC)","status":"COMPLETED","sponsor":"Shanghai MicroPort Medical (Group) Co., Ltd.","startDate":"2015-12","conditions":"Coronary Artery Disease","enrollment":1653},{"nctId":"NCT04203901","phase":"PHASE2","title":"Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma","status":"TERMINATED","sponsor":"CoImmune","startDate":"2020-07-22","conditions":"Advanced Renal Cell Carcinoma","enrollment":16},{"nctId":"NCT01827384","phase":"PHASE2","title":"MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-01-07","conditions":"Advanced Malignant Solid Neoplasm","enrollment":208},{"nctId":"NCT01298713","phase":"PHASE2","title":"Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2008-03","conditions":"Breast Neoplasms, mTor Protein","enrollment":111},{"nctId":"NCT02031536","phase":"PHASE2","title":"Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2014-04-10","conditions":"Gastrinoma, Glucagonoma, Insulinoma","enrollment":2},{"nctId":"NCT03468478","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2017-06-18","conditions":"Kidney Transplant Infection","enrollment":1209},{"nctId":"NCT01332279","phase":"PHASE1","title":"Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy","status":"WITHDRAWN","sponsor":"Fox Chase Cancer Center","startDate":"2011-04","conditions":"Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx","enrollment":""},{"nctId":"NCT02776644","phase":"","title":"Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-10-15","conditions":"Renal Cell Carcinoma","enrollment":1349},{"nctId":"NCT02913261","phase":"PHASE3","title":"Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-03-10","conditions":"Corticosteroid Refractory Acute Graft vs Host Disease","enrollment":310},{"nctId":"NCT00805129","phase":"PHASE2","title":"Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-12-05","conditions":"Bladder Cancer, Metastatic Transitional Cell Carcinoma","enrollment":46},{"nctId":"NCT01976390","phase":"NA","title":"Comparing Everolimus and Sirolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2013-10-01","conditions":"Renal Failure","enrollment":60},{"nctId":"NCT02444390","phase":"NA","title":"Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2015-05-19","conditions":"Metastatic Breast Cancer","enrollment":150},{"nctId":"NCT00981162","phase":"PHASE1","title":"Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2009-08","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer","enrollment":12},{"nctId":"NCT02441543","phase":"","title":"Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus","status":"COMPLETED","sponsor":"Istituto Clinico Humanitas","startDate":"2015-04","conditions":"SOLID TUMOR","enrollment":45},{"nctId":"NCT02205515","phase":"PHASE1, PHASE2","title":"An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2016-03","conditions":"Carcinoma, Neuroendocrine","enrollment":17},{"nctId":"NCT01582009","phase":"PHASE1, PHASE2","title":"Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2010-03","conditions":"Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer","enrollment":26},{"nctId":"NCT03805399","phase":"PHASE1, PHASE2","title":"FUSCC Refractory TNBC Umbrella (FUTURE)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2018-10-18","conditions":"Triple-negative Breast Cancer","enrollment":140},{"nctId":"NCT01229943","phase":"PHASE2","title":"Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-15","conditions":"Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma","enrollment":150},{"nctId":"NCT04355858","phase":"PHASE2","title":"Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-05-01","conditions":"Breast Cancer, Metastatic Cancer","enrollment":319},{"nctId":"NCT02120469","phase":"PHASE1","title":"Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2014-10-01","conditions":"Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor-negative","enrollment":27},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT01935128","phase":"PHASE4","title":"Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction","status":"COMPLETED","sponsor":"University of Toledo Health Science Campus","startDate":"2013-07-03","conditions":"Renal Transplant","enrollment":55},{"nctId":"NCT01154335","phase":"PHASE1","title":"Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2010-07","conditions":"Metastatic Colorectal Cancer","enrollment":18},{"nctId":"NCT02269670","phase":"PHASE2","title":"Phase II Study of Everolimus Beyond Progression","status":"TERMINATED","sponsor":"Emory University","startDate":"2014-11-25","conditions":"Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer","enrollment":3},{"nctId":"NCT03239015","phase":"PHASE2","title":"Efficacy and Safety of Precision Therapy in Refractory Tumor","status":"UNKNOWN","sponsor":"Baodong Qin","startDate":"2017-01-01","conditions":"Rare Tumor, Refractory Tumor","enrollment":300},{"nctId":"NCT00886691","phase":"PHASE2","title":"Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"GOG Foundation","startDate":"2010-12-27","conditions":"Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":150},{"nctId":"NCT01218555","phase":"PHASE1","title":"Study of Everolimus (RAD001) in Combination With Lenalidomide","status":"COMPLETED","sponsor":"Emory University","startDate":"2010-09-09","conditions":"Solid Organ Malignancies, Adenoidcystic Carcinoma, Neuroendocrine Tumors","enrollment":44},{"nctId":"NCT02484664","phase":"PHASE2","title":"COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-06-15","conditions":"Lymphangioleiomyomatosis (LAM)","enrollment":12},{"nctId":"NCT03139747","phase":"PHASE2","title":"UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone","status":"SUSPENDED","sponsor":"Thomas Jefferson University","startDate":"2017-04-03","conditions":"Thyroid Cancer","enrollment":5},{"nctId":"NCT03387020","phase":"PHASE1","title":"Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors","status":"COMPLETED","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2018-01-13","conditions":"CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma, Recurrent Atypical Teratoid/Rhabdoid Tumor","enrollment":22},{"nctId":"NCT01929642","phase":"PHASE2","title":"Rapalogues for Autism Phenotype in TSC: A Feasibility Study","status":"COMPLETED","sponsor":"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.","startDate":"2013-07","conditions":"Tuberous Sclerosis Complex, Self-injury, Autism","enrollment":3},{"nctId":"NCT01624766","phase":"PHASE1","title":"Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-06-19","conditions":"Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm","enrollment":57},{"nctId":"NCT00622258","phase":"PHASE1","title":"A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-03","conditions":"Non-Hodgkin's Lymphoma","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":599,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["switch immunosuppression to everolimus"],"phase":"marketed","status":"active","brandName":"mTOR inhibitor (everolimus)","genericName":"mTOR inhibitor (everolimus)","companyName":"Hannover Medical School","companyId":"hannover-medical-school","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation. Used for Advanced renal cell carcinoma, Breast cancer (hormone receptor-positive, HER2-negative), Neuroendocrine tumors of pancreatic origin.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}